Evidence-based·Last reviewed May 31, 2026·How we grade evidence

Sodium Butyrate

Fatty-acidShort-chain fatty acidBest with a meal

A short-chain fatty acid your gut bacteria already make from dietary fiber. The colonocyte-energy and gut-barrier mechanisms are solid; the clinical evidence in humans is thin. Enema studies in ulcerative colitis are mixed and a 2021 systematic review concluded the current evidence does NOT support their routine use. Oral microencapsulated forms have small IBS trials.

Quick decision guide

May help most

People with IBS-D or functional bowel symptoms looking for a low-risk adjunct; not a substitute for standard IBD/IBS therapy.

Common dosing range

150–600 mg/day oral microencapsulated sodium butyrate (or 300 mg twice daily) in the IBS trials.

When to expect effects

4–12 weeks for symptomatic effects in IBS trials.

Watch out for

Most marketing extrapolates from mechanism or animal data — the human RCT base is small. Don't replace established IBD or IBS treatment with butyrate.

Evidence snapshot

Gut-barrier mechanism (colonocyte energy, tight junctions)Strong (mechanism)
Irritable bowel syndrome (oral, small RCTs)Emerging
Ulcerative colitis (rectal enemas)Low / mixed
Crohn's diseaseLow
Colorectal cancer preventionLow (mechanism only)
Constipation, metabolic, autism — direct evidenceLow

What is it

Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid produced naturally in the colon when gut bacteria ferment dietary fiber. As a supplement, it is used to deliver butyrate directly to the gastrointestinal tract for digestive and metabolic support.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have IBS (especially IBS-D or mixed pattern) and want a low-risk adjunct alongside dietary changes
You're already on standard IBD therapy and your gastroenterologist supports an adjunct trial
You have a low-fiber diet you can't easily change and want a partial workaround for low endogenous butyrate production (much weaker case than just eating more fiber)
You've tried mainstream IBS treatments without success and want to try a low-risk add-on
You're looking at a microencapsulated oral product (not raw sodium butyrate, which smells terrible and degrades in the stomach)

Probably skip if…

You're trying to replace 5-ASA, biologics, or other standard IBD therapy with butyrate — evidence does not support this
Your goal is colorectal cancer prevention — the mechanism is plausible but no clinical trials exist
You're hoping for autism, mood, or metabolic effects from oral butyrate — no human RCT base
You'd rather eat more fiber, fermented foods, and resistant starch — your gut bacteria produce 400+ mmol of SCFA daily on a fiber-rich diet
Cost is a concern — increasing dietary fiber is cheaper and supported by far more evidence

Evidence at a glance

Irritable bowel syndrome (oral microencapsulated)

Limited Evidence
Effect
Reduced frequency of abdominal pain, postprandial pain, and BM-associated pain vs placebo at 12 weeks (n=66); no significant effect on severity
Best fit
Adults with IBS (any subtype) looking for a low-risk adjunct to dietary and behavioral therapy
Time
4–12 weeks

Ulcerative colitis (rectal enemas)

Mixed Evidence
Effect
Inconsistent across trials; pooled evidence does not support clinically meaningful benefit
Best fit
Patients with refractory distal UC under a gastroenterologist's care who want to try an adjunct after standard therapy
Time
Weeks

Gut barrier function / 'leaky gut'

Mixed Evidence
Effect
Strong preclinical mechanism; limited and inconsistent human permeability/clinical data
Best fit
People with documented intestinal permeability issues (rare) considering adjuncts to dietary changes
Time
Not characterized in humans

Crohn's disease

Weak Evidence
Effect
No reliable estimate — adequate trials don't exist
Best fit
No one as primary therapy
Time
Not established

Colorectal cancer prevention

Weak Evidence
Effect
Strong preclinical mechanism; no human prevention or treatment trials
Best fit
Researchers; people acting on preclinical signal
Time
Not established

Evidence for 5 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Irritable bowel syndrome (oral microencapsulated)

Supplement benefit
Limited Evidence

A 12-week placebo-controlled trial of microencapsulated sodium butyrate (300 mg/day) added to standard therapy in 66 IBS patients (Banasiewicz 2013) found a significant reduction in the frequency of abdominal pain, postprandial pain, and bowel-movement-associated pain vs placebo, without significant effect on overall symptom severity. A few subsequent small trials and open-label studies have shown similar directionality. Effect sizes are modest and replication in large independent RCTs is limited.

Effect size
Reduced frequency of abdominal pain, postprandial pain, and BM-associated pain vs placebo at 12 weeks (n=66); no significant effect on severity
Time to effect
4–12 weeks
Best fit
Adults with IBS (any subtype) looking for a low-risk adjunct to dietary and behavioral therapy
Less likely
Severe IBS not responding to multiple standard therapies (try gastroenterologist-supervised options like rifaximin, eluxadoline, or low-FODMAP first)

Bottom line: A reasonable adjunct in IBS based on small but positive RCT data. Use a microencapsulated product; don't expect dramatic effects.

SourceBanasiewicz et al., 2013 — Colorectal Disease

Ulcerative colitis (rectal enemas)

Disease adjunct
Mixed Evidence

Early small trials (Scheppach 1992, Vernia 1995) showed butyrate enemas could improve symptoms and endoscopic inflammation in distal ulcerative colitis vs placebo. Larger and more rigorous follow-up trials (Steinhart 1996) failed to show benefit. A 2021 systematic review of 8 RCTs (227 UC patients) concluded the current evidence is LIMITED and does NOT support routine clinical use of butyrate enemas in UC. Practical issues (twice-daily enemas, butyrate smell, patient acceptance) are also significant.

Effect size
Inconsistent across trials; pooled evidence does not support clinically meaningful benefit
Time to effect
Weeks
Best fit
Patients with refractory distal UC under a gastroenterologist's care who want to try an adjunct after standard therapy
Less likely
Most UC patients — use established 5-ASA, corticosteroid, or biologic therapy

Bottom line: Not recommended as a routine UC therapy. Talk to your gastroenterologist before trying.

Evidence is mixed

Early small positive trials (Scheppach 1992, Vernia 1995) were not replicated in larger trials (Steinhart 1996), and the 2021 systematic review concluded evidence does NOT support routine clinical use.

SourceScheppach et al., 1992 — Gastroenterology· conflictingSteinhart et al., 1996 — Alimentary Pharmacology & Therapeutics· conflictingJamka et al., 2021 — Complementary Medicine Research· conflicting
SourceJamka et al., 2021 — Complementary Medicine ResearchScheppach et al., 1992 — Gastroenterology

Gut barrier function / 'leaky gut'

Mechanism only
Mixed Evidence

Butyrate is the preferred energy substrate of colonocytes and supports tight-junction proteins (occludin, claudin), which is the mechanistic basis for the 'gut barrier support' claim. In vitro and animal data are strong; human RCTs measuring intestinal permeability or clinical 'leaky gut' outcomes are sparse and inconsistent. Most marketing claims extrapolate from mechanism rather than human trial data.

Effect size
Strong preclinical mechanism; limited and inconsistent human permeability/clinical data
Time to effect
Not characterized in humans
Best fit
People with documented intestinal permeability issues (rare) considering adjuncts to dietary changes
Less likely
Anyone with general 'leaky gut' concerns without medical workup — dietary fiber and fermented foods are the more evidence-based path

Bottom line: Plausible mechanism; weak human evidence. Increasing dietary fiber gets you more butyrate at the colon than oral supplementation typically does.

SourceStoeva et al., 2021 — Gut Microbes

Crohn's disease

Disease adjunct
Weak Evidence

Very small pilot studies of oral butyrate in mild-to-moderate Crohn's have shown some symptomatic improvement, but no adequately powered RCT exists. The 2021 systematic review found no reliable enema data either. Not a substitute for standard Crohn's therapy.

Effect size
No reliable estimate — adequate trials don't exist
Time to effect
Not established
Best fit
No one as primary therapy
Less likely
Anyone hoping to use it instead of standard immunomodulator/biologic therapy

Bottom line: Not evidence-based for Crohn's. Use established treatment.

SourceJamka et al., 2021 — Complementary Medicine Research

Colorectal cancer prevention

Mechanism only
Weak Evidence

Butyrate has well-documented anti-proliferative and pro-apoptotic effects on colorectal cancer cells in vitro (the 'butyrate paradox' — selectively cytotoxic to malignant colonocytes). No human prevention trials have demonstrated supplemental butyrate reduces colorectal cancer incidence or recurrence. Dietary fiber, which generates intracolonic butyrate, has more robust epidemiological CRC-prevention evidence.

Effect size
Strong preclinical mechanism; no human prevention or treatment trials
Time to effect
Not established
Best fit
Researchers; people acting on preclinical signal
Less likely
Anyone expecting demonstrated cancer prevention from supplementation

Bottom line: Eat more fiber for the colorectal-cancer-prevention case. Supplemental butyrate is not a substitute.

SourceStoeva et al., 2021 — Gut Microbes

How it works

Butyrate is the primary energy source for colonocytes (cells lining the colon), accounting for up to 70% of their energy supply. By feeding the colon lining, butyrate supports gut barrier integrity, mucin production, and tight junction function, which collectively help prevent leaky gut and reduce systemic inflammation. Research suggests butyrate has anti-inflammatory effects in the gut, mediated by inhibition of NF-kB signaling and modulation of regulatory T-cell function. It also acts as a histone deacetylase (HDAC) inhibitor, with epigenetic effects on gene expression that may influence cell differentiation, apoptosis, and metabolism. Butyrate has been investigated for inflammatory bowel disease, irritable bowel syndrome, and metabolic conditions. The challenge with supplemental butyrate is delivering it to the colon intact: free butyrate (like sodium butyrate) is rapidly absorbed in the upper GI tract and may not reach the colon in meaningful amounts unless protected by enteric coating or delivered as a precursor like tributyrin.

How to take it

1. Typical dose
• Oral microencapsulated sodium butyrate: 150–600 mg/day (IBS trial dose: 300 mg/day, sometimes split as 150 mg twice daily) • Higher doses (1–2 g/day) used in some open-label studies but not directly compared to lower doses for additional benefit • Enema dosing (UC, by gastroenterologist): 60–100 mmol/L solutions twice daily — practical issues limit adoption
2. Higher studied dose
Up to 1.8 g/day microencapsulated has been used in IBD pilot studies; safety is good but additional benefit over 300 mg/day is not established.
3. Timing
With or between meals; microencapsulation is designed to protect butyrate from the stomach so timing relative to food matters less than with non-encapsulated forms.
4. With food
Either.
5. Split dosing
Splitting (e.g., 150 mg twice daily) is the most common protocol in IBS trials.
6. How long to try
Give at least 8–12 weeks for IBS symptomatic effects before judging. If no benefit at 12 weeks, discontinue. Long-term safety beyond 6 months is not well characterized.

What to track

IBS symptom severity score (frequency and severity of abdominal pain, bloating, bowel habit)
Bowel movement consistency (Bristol Stool Scale)
Tolerability (the smell of butyrate is famously bad — even microencapsulated products can cause burping with butyric odor)
Whether you'd get more benefit from increasing dietary fiber and fermented foods instead

Bottom line: Try 300 mg/day of a microencapsulated product for 8–12 weeks for IBS symptoms. Don't expect dramatic effects. Increasing fiber is a cheaper, better-evidenced way to raise intracolonic butyrate.

5 commercial forms

Compare the main delivery options and what they’re best suited for.

Microencapsulated sodium butyrate

Standard oral form

Coating designed to protect butyrate from stomach acid so it reaches the colon. The form used in the IBS trial (Banasiewicz 2013).

Encapsulation matters — raw sodium butyrate is largely absorbed/degraded before reaching the colon.

Calcium-magnesium butyrate (CalMag butyrate)

Sodium-free alternative

Avoids the small sodium load; same mechanism. Limited direct head-to-head comparisons, but generally interchangeable for clinical purposes.

Comparable to sodium butyrate when microencapsulated.

Sodium butyrate enema (compounded)

Rectal use

Used in UC trials at 60–100 mmol/L twice daily. Practical issues (smell, twice-daily protocol) and inconsistent efficacy data limit adoption. Requires a gastroenterologist's involvement and a compounding pharmacy.

Direct mucosal delivery to the distal colon; the strongest mechanistic case for an exposure route.

Tributyrin (butyrate triglyceride)

Alternative SCFA pro-drug

Three butyrate molecules esterified to glycerol; cleaved in the gut to release butyrate. Some early-stage interest as an oral delivery method but very limited human data.

Designed to bypass the rapid colonic uptake of free butyrate; clinical evidence is still preliminary.

Dietary fiber and resistant starch (the indirect route)

Best-evidenced butyrate strategy

Your colonic bacteria ferment fiber and resistant starch into butyrate, propionate, and acetate. A high-fiber diet generates more total butyrate at the colon than oral butyrate supplementation, and the epidemiological evidence for fiber's gut and metabolic benefits is dramatically stronger.

Endogenous production; the most physiological way to raise colonic butyrate.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

unpleasant butyric (rancid butter) breath/burps with non-microencapsulated formsmild gas or bloatingoccasional loose stools

Serious risks

  • Sodium butyrate adds a small amount of sodium to the diet (≈55 mg sodium per 300 mg butyrate dose). Trivial in most people but worth noting on a strict low-sodium diet (CHF, advanced CKD).

  • Long-term safety beyond 6–12 months has not been rigorously studied in humans.

Who should avoid it

  • People on strict sodium restriction (advanced heart failure, severe CKD) should choose a calcium-magnesium butyrate alternative or skip.
  • Pregnancy and lactation — no adequate human data on oral supplementation; stick to dietary fiber for butyrate production.
  • People with active severe IBD flares should not self-substitute butyrate for established 5-ASA, corticosteroid, or biologic therapy.

Pregnancy & breastfeeding

There are no adequate human studies of oral sodium butyrate supplementation in pregnancy or lactation. Endogenous butyrate from dietary fiber is normal and safe. Avoid supplemental forms during pregnancy unless directed by your obstetrician.

Bottom line: Generally well-tolerated at studied doses. The biggest 'risk' is wasting money on a marginal-evidence product when dietary fiber would do more for less.

Interactions

histone deacetylase (HDAC) inhibitor cancer therapies (e.g., vorinostat, romidepsin)Minor

Butyrate has weak HDAC inhibitor activity in vitro. Clinically relevant interaction with pharmaceutical HDAC inhibitors is unlikely at oral supplemental doses, but worth flagging if you're on these cancer therapies.

no major established drug interactionsMinor

Sodium butyrate at oral doses used in trials has no well-documented drug interactions beyond minor sodium addition.

Food sources

Butter (preformed butyrate)

Amount
1 Tbsp (~150 mg)
%DV
—

Ghee (preformed butyrate)

Amount
1 Tbsp (~200 mg)
%DV
—

Parmesan cheese (small amount preformed)

Amount
1 oz (~25 mg)
%DV
—

Resistant starch (cooled potato, banana) — fermented to butyrate by gut bacteria

Amount
1 cup serving
%DV
—

Wheat bran / oat bran — fiber fermented to butyrate

Amount
30 g serving
%DV
—

Beans, lentils, chickpeas — fiber fermented to butyrate

Amount
1 cup cooked
%DV
—

Choosing a product

What to look for on the label — and what to be skeptical of.

Look for…

Microencapsulated formulation — required for oral use; raw sodium butyrate degrades in the stomach and tastes/smells terrible
Clear sodium butyrate content per capsule (typically 150–300 mg)
Third-party tested (USP, NSF, Informed Choice)
Calcium-magnesium butyrate (CalMag-butyrate) alternative if you're avoiding added sodium
Single-ingredient products easier to dose precisely than multi-ingredient 'gut health' stacks

Be skeptical of…

'Heals leaky gut' — human evidence is sparse and inconsistent
'Treats IBD' or 'replaces biologics' — only enema studies exist, mostly negative, and oral data are absent
'Prevents colon cancer' — no human prevention trial
'Boosts mood and reduces anxiety via the gut-brain axis' — extrapolation from animal data, no human RCT
'Better than eating fiber' — your gut bacteria can make 400+ mmol of SCFA per day from a fiber-rich diet, far more than oral supplementation delivers

Frequently asked questions

What is butyrate good for?⌄

Butyrate is the primary fuel for colon cells and supports gut barrier function, anti-inflammatory pathways, and intestinal health. It has been investigated for IBD, IBS, and various metabolic conditions.

Will sodium butyrate reach my colon?⌄

Plain sodium butyrate is rapidly absorbed in the upper GI and may not deliver much to the colon. Enteric-coated forms or tributyrin (triglyceride form) are more effective for colonic delivery.

Can I get enough butyrate from food?⌄

The most effective dietary strategy is consuming fermentable fiber, which gut bacteria convert to butyrate in the colon. Direct dietary sources (butter, ghee) provide small amounts.

Does sodium butyrate cause body odor?⌄

Butyrate has a strong rancid smell. Enteric-coated or alternative delivery forms reduce odor. Some users report transient breath or body odor effects.

Is sodium butyrate safe to take long-term?⌄

Short-to-medium term use appears well tolerated. Long-term safety beyond a year has not been extensively studied. Monitor sodium intake if using larger doses.

References by claim

Ulcerative colitis (rectal enemas)

Scheppach et al., 1992 — Gastroenterology (1992) link

Steinhart et al., 1996 — Alimentary Pharmacology & Therapeutics (1996) link

Jamka et al., 2021 — Complementary Medicine Research (2021) link

Irritable bowel syndrome (oral microencapsulated)

Banasiewicz et al., 2013 — Colorectal Disease (2013) link

Gut barrier function / 'leaky gut'

Stoeva et al., 2021 — Gut Microbes (2021) link

Other references

Vernia et al., 1995 — Alimentary Pharmacology & Therapeutics (1995) link

Sodium Butyrate on Wikidata — Wikidata link

Sodium Butyrate on ChEBI — ChEBI link

Sodium Butyrate (PubChem CID 5222465) — PubChem link

Track Sodium Butyrate with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store
Evidence-based·Last reviewed May 31, 2026·Evidence current as of May 31, 2026·How we grade evidence

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.